Michael Hanley

Michael Hanley joined Alto as our Chief Operating Officer in May 2024. He brings over 25 years of leadership experience in life sciences, most of which focused on CNS-related disorders. Mr. Hanley’s career spans across the product life cycle from early-stage new product planning and portfolio strategy to product launch and brand management. Prior to Alto, Mr. Hanley served as Chief Commercial Officer and Chief Business Officer at Aeglea BioTherapeutics, General Manager at Horizon Therapeutics, and Head of US Sales for Lundbeck’s psychiatry business unit, where he was responsible for managing TRINTELLIX (vortioxetine) and ABILIFY MAINTENA (aripiprazole) and preparing for the launch of REXULTI (brexpiprazole). Throughout his career, Mr. Hanley has worked and held leadership roles in a wide range of neuropsychiatric indications, including major depressive disorder, schizophrenia, sleep disorders, epilepsy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Mr. Hanley received a BBA in marketing from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.